Genasense Progression-Free Survival Data Do Not Show “Real Effect,” Cmte.
Executive Summary
Genta/Aventis Genasense appears to have a "real effect" on response rates in metastatic melanoma patients but not on progression-free survival or survival, FDA's Oncologic Drugs Advisory Committee concluded at its May 3 meeting
You may also be interested in...
Genasense Accelerated Approval Not Supported Due To Failed Outcomes Data
Accelerated approval based on response rate is not appropriate for Genta's Genasense given the Bcl-2 inhibitor's failure to show a benefit on clinical outcomes in a randomized Phase III trial, FDA and members of its Oncologic Drugs Advisory Committee said during a Sept. 6 meeting
Genasense Accelerated Approval Not Supported Due To Failed Outcomes Data
Accelerated approval based on response rate is not appropriate for Genta's Genasense given the Bcl-2 inhibitor's failure to show a benefit on clinical outcomes in a randomized Phase III trial, FDA and members of its Oncologic Drugs Advisory Committee said during a Sept. 6 meeting
Aventis, Genta To Meet With FDA After Genasense NDA Withdrawal
Aventis will participate in Genta's meeting with FDA following the withdrawal of the new drug application for Genasense